Flagship Ventures Fund IV-Rx, L.P., 10% Owner at Evelo Biosciences, Inc. (EVLO), bought 54,794,518 shares at $1.46 ($80.0M) on 2022-05-27, disclosed to the SEC on 2022-06-01.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.46 | 1,095,890 | $1.6M | 2.0% |
| 2 | $1.46 | 1,095,890 | $1.6M | 2.0% |
| 3 | $1.46 | 1,369,863 | $2.0M | 2.5% |
| 4 | $1.46 | 1,369,863 | $2.0M | 2.5% |
| 5 | $1.46 | 4,383,561 | $6.4M | 8.0% |
| 6 | $1.46 | 4,383,561 |
| $6.4M |
| 8.0% |
| 7 | $1.46 | 6,849,315 | $10.0M | 12.5% |
| 8 | $1.46 | 6,849,315 | $10.0M | 12.5% |
| 9 | $1.46 | 13,698,630 | $20.0M | 25.0% |
| 10 | $1.46 | 13,698,630 | $20.0M | 25.0% |
| Total | $1.46 avg | 54,794,518 | $80.0M | 100% |
| Filing → |